Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis-Reference-Cited by-同舟云学术

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis

Published:2020-12 Issue:4 Volume:87 Page:2078-2088
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Rajoli Rajith K. R.¹^ORCID,Pertinez Henry¹,Arshad Usman¹^ORCID,Box Helen¹,Tatham Lee¹^ORCID,Curley Paul¹^ORCID,Neary Megan¹^ORCID,Sharp Joanne¹,Liptrott Neill J.¹^ORCID,Valentijn Anthony¹,David Christopher¹^ORCID,Rannard Steven P.²^ORCID,Aljayyoussi Ghaith³^ORCID,Pennington Shaun H.³^ORCID,Hill Andrew¹^ORCID,Boffito Marta⁴⁵^ORCID,Ward Steve A.³^ORCID,Khoo Saye H.¹^ORCID,Bray Patrick G.⁶,O'Neill Paul M.²,Hong W. David²,Biagini Giancarlo A.³,Owen Andrew¹^ORCID

Affiliation:

1. Department of Molecular and Clinical Pharmacology, Materials Innovation Factory University of Liverpool Liverpool UK

2. Department of Chemistry University of Liverpool Liverpool UK

3. Centre for Drugs and Diagnostics, and Department of Tropical Disease Biology Liverpool School of Tropical Medicine Liverpool UK

4. Chelsea and Westminster NHS Foundation Trust and St Stephen's AIDS Trust 4th Floor Chelsea and Westminster Hospital London UK

5. Jefferiss Research Trust Laboratories, Department of Medicine Imperial College London UK

6. Pat Bray Electrical Orrell Wigan UK

Funder

Medical Research Council Canada

European Commission

National Institutes of Health

Engineering and Physical Sciences Research Council

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14619

Reference70 articles.

1. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections

2. Johns Hopkins University of Medicine.Coronavirus Resource Center. 2020 [cited 2020 17/04/2020]; Available from:https://coronavirus.jhu.edu/map.html

3. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

4. An update on Drug Repurposing: Re-written saga of the drug’s fate

5. Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial intelligence for drug repurposing against infectious diseases;Artificial Intelligence Chemistry;2024-12

2. Glucuronidation of tizoxanide, an active metabolite of nitazoxanide, in liver and small intestine: Species differences in humans, monkeys, dogs, rats, and mice and responsible UDP-glucuronosyltransferase isoforms in humans;Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology;2024-09

3. Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19;Viruses;2024-05-28

4. Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers;Future Pharmacology;2024-02-22

5. Thoughts on plagiarism and the case against Claudine Gay;Journal of Pharmacokinetics and Pharmacodynamics;2024-02